106 related articles for article (PubMed ID: 2316207)
1. Development of an immunoaffinity process for factor IX purification.
Tharakan J; Strickland D; Burgess W; Drohan WN; Clark DB
Vox Sang; 1990; 58(1):21-9. PubMed ID: 2316207
[TBL] [Abstract][Full Text] [Related]
2. Immunopurification of human coagulation factor IX using monoclonal antibodies.
Bessos H; Prowse CV
Thromb Haemost; 1986 Aug; 56(1):86-9. PubMed ID: 3775693
[TBL] [Abstract][Full Text] [Related]
3. Effect of feed flow-rate, antigen concentration and antibody density on immunoaffinity purification of coagulation factor IX.
Tharakan JP; Clark DB; Drohan WN
J Chromatogr; 1990 Nov; 522():153-62. PubMed ID: 2081750
[TBL] [Abstract][Full Text] [Related]
4. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
Liebman HA; Limentani SA; Furie BC; Furie B
Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3879-83. PubMed ID: 2408269
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CNBr, FMP and hydrazide resins for immunoaffinity purification of factor IX.
Highsmith F; Regan T; Clark D; Drohan W; Tharakan J
Biotechniques; 1992 Mar; 12(3):418-23. PubMed ID: 1571154
[TBL] [Abstract][Full Text] [Related]
6. Rapid purification of factor IX, factor X and prothrombin by immunoaffinity and ion exchange chromatography.
Ahmad SS; Rawala-Sheikh R; Thompson AR; Walsh PN
Thromb Res; 1989 Jul; 55(1):121-33. PubMed ID: 2781515
[TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of rabbit factor IX and its existence as a two-chain factor IX alpha in circulating plasma.
Rao LV; Hoang AD
Thromb Res; 1991 Oct; 64(1):57-68. PubMed ID: 1776139
[TBL] [Abstract][Full Text] [Related]
8. Immunoaffinity purification of protein C by using conformation-specific monoclonal antibodies to protein C-calcium ion complex.
Nakamura S; Sakata Y
Biochim Biophys Acta; 1987 Aug; 925(2):85-93. PubMed ID: 3620498
[TBL] [Abstract][Full Text] [Related]
9. Physical and biochemical characterization of five commercial resins for immunoaffinity purification of factor IX.
Tharakan J; Highsmith F; Clark D; Drohan W
J Chromatogr; 1992 Mar; 595(1-2):103-11. PubMed ID: 1577903
[TBL] [Abstract][Full Text] [Related]
10. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG
Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674
[TBL] [Abstract][Full Text] [Related]
11. Separation of human plasma factor IX from HTLV-I or HIV by immunoaffinity chromatography using conformation-specific antibodies.
Limentani SA; Furie BC; Poiesz BJ; Montagna R; Wells K; Furie B
Blood; 1987 Nov; 70(5):1312-5. PubMed ID: 2822170
[TBL] [Abstract][Full Text] [Related]
12. Homologous human blood protein separation using immobilized metal affinity chromatography: protein C separation from prothrombin with application to the separation of factor IX and prothrombin.
Wu H; Bruley DF
Biotechnol Prog; 1999; 15(5):928-31. PubMed ID: 10514264
[TBL] [Abstract][Full Text] [Related]
13. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane.
Berndt MC; Gregory C; Kabral A; Zola H; Fournier D; Castaldi PA
Eur J Biochem; 1985 Sep; 151(3):637-49. PubMed ID: 3161731
[TBL] [Abstract][Full Text] [Related]
14. Purification of six human vitamin K-dependent proteins in a single chromatographic step using immunoaffinity columns.
Jenny R; Church W; Odegaard B; Litwiller R; Mann K
Prep Biochem; 1986; 16(3):227-45. PubMed ID: 3748998
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
[TBL] [Abstract][Full Text] [Related]
16. Use of proteomics for validation of the isolation process of clotting factor IX from human plasma.
Clifton J; Huang F; Gaso-Sokac D; Brilliant K; Hixson D; Josic D
J Proteomics; 2010 Jan; 73(3):678-88. PubMed ID: 19819359
[TBL] [Abstract][Full Text] [Related]
17. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
18. Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports.
Ribeiro DA; Passos DF; Ferraz HC; Castilho LR
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 938():111-8. PubMed ID: 24076525
[TBL] [Abstract][Full Text] [Related]
19. Preparation and properties of a therapeutic factor IX concentrate.
Suomela H; Myllylä G; Raaska E
Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
[TBL] [Abstract][Full Text] [Related]
20. Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5.
Chang YJ; Wu HL; Hsu YC; Hamaguchi N; Shi GY; Shen MC; Lin SW
Thromb Res; 2003; 111(4-5):293-9. PubMed ID: 14693178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
